Hematologic cancer patients who develop renal complications during treatment incur hospital costs that are twice as high as patients without renal problems, according to findings presented here at the annual meeting of The American Society of Hematology.
If dialysis is required, the cost is nearly five times higher. Many of the drugs used to treat hematologic malignancies can produce tumor lysis syndrome, resulting in elevated uric acid levels that can lead to renal failure. However, the economic burden of these treatment-related complications has been unclear.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!